Hepatic veno-occlusive disease (VOD), or sinusoidal obstructive syndrome (SOS), is a clinical syndrome characterized by hepatomegaly, ascites, weight gain and jaundice, which can develop more frequently in the first 30 days after hematopoietic stem cell transplantation (HSCT).
The diagnosis of VOD is primarily based on established clinical criteria (modified Seattle or Baltimore criteria); [6] [7] [8] [9] ultrasound imaging may be helpful in the exclusion of other disorders in patients with suspected VOD. Liver biopsy should be reserved for patients in whom the diagnosis of VOD is unclear and other diagnoses need to be excluded. 10 Liver stiffness (LS) measurement using Fibroscan is a new safe, accurate and non-invasive method used to better identify liver fibrosis and degree of portal hypertension 11, 12 in chronic liver disease patients. LS measurement was carried out using FibroScan (Echosens, Paris, France) after at least 6 h of fasting, as previously described. 13 Briefly, the FibroScan device consists of a 3.5 MHz ultrasound transducer probe mounted on the axis of a vibrator. Mild amplitude and low-frequency vibrations (50 Hz) are transmitted to the liver tissue, inducing an elastic shear wave, which propagates through the underlying tissue. Transient elastography (TE) measurement assesses the stiffness of the liver, which is used as an indirect marker of liver fibrosis. Furthermore, its measurement is useful in predicting the degree of portal hypertension. For each patient, the physician carried out at least 10 valid A recent paper has shown that LS measurement using ARFI (Acoustic Radiation Force Impulse) and Fibroscan could represent an additional diagnostic parameter for adult patients with suspected post-transplant hepatic injury; in fact, LS pretransplant values using ARFIo 1.25 m/s were correlated with the absence of severe complications after allo-HSCT. 14 The aim of our study was to verify the role of LS measurement in predicting VOD development in a pediatric population who underwent HSCT using Fibroscan.
The data presented herein are interim data from a prospective single-center study, which is currently in progress. All consecutive patients referred to the Hemato-Oncologic Pediatric Unit of Sant'Orsola Hospital, from November 2014 to May 2016, with hemato-oncologic disease with indications for allo-and auto-SCT were enrolled. Of the patients having indications for auto-SCT, those who underwent TBI or a busulfan-based conditioning regimen were enrolled. The inclusion criteria were: informed consent, age 4-70 years and patients affected by hematooncologic disease with any indications for allo-SCT or with indications for auto-SCT after TBI or busulfan-based chemotherapy. The exclusion criteria were obesity (body mass index 440), pacemakers or implantable defibrillators and the presence of ascites.
The baseline demographic and clinical characteristics of the patients were recorded. At enrollment (before pre-HSCT chemotherapy), all patients underwent laboratory tests, routine abdomen ultrasonography examination and LS measurement. Laboratory tests and LS measurement were subsequently carried out at 7-10 days (T1), 17-20 days (T2) and 27-30 days (T3) after transplantation. All examinations were conducted at bedside to minimize the risk of infection.
The study was carried out in accordance with the ethical guidelines of the Helsinki Declaration and was approved by the local ethics committee. All study participants provided written informed consent.
GvHD was diagnosed using the Glucksberg et al. 15 criteria; drugrelated hepatotoxicity was diagnosed according to the recent Meeting Report by Fontana et al., 16 for example, patients who developed severe direct hyperbilirubinemia in an extremely early phase of post transplant (on days +2 and +5) without other clinical VOD manifestations or any other causes, such as infections, GvHD and biliary obstructive causes were also excluded.
The VOD was diagnosed according to the modified Seattle or Baltimore criteria. 7, 8 The severity of the VOD was assessed according to Carreras et al. 17 and McDonald et al.
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During the study period, 22 (16 males, 6 females, mean age: 140 months, min 54, max 245) out of 30 patients who had undergone HSCT were enrolled according to the previously defined inclusion criteria. The indication for HSCT, and the baseline clinical and demographic characteristics of the patients enrolled are shown in Table 1 .
With the exception of patients 5, 20 and 22 who had Ewing's sarcoma and had undergone autologous transplantation, all patients underwent allogeneic transplantation. The TE measurement was successful in all patients; none had ascites during TE assessment, as documented by the preliminary ultrasonographic examination. The LS value for each assessment and the VOD diagnosis are shown in Figure 1 ; no evident differences were observed at baseline LS values between patients who developed VOD and those who did not. Of the patients who developed VOD, patient 2 had an increase in LS 18 days after HSCT, developing VOD 4 days later; patient 4 had an increase in LS 17 days after HSCT, developing VOD 5 days later; patient 5 had an increase in LS 18 days after HSCT, developing VOD 6 days later and patient 17 had an increase in LS 16 days after HSCT, developing VOD 3 days later. The LS values increased in the measurement carried out before VOD diagnosis, and these values were different from the baseline and the from previous values. In the two patients who developed liver toxicity, there was a gradual and early increase in LS, starting from the fifth day after HSCT. Of these patients, the first one had spontaneous resolution of the liver toxicity and the second one developed multi-organ failure and died on day 44 after HSCT.
These initial data showed that the increase in LS values seemed to predict VOD development after HSCT in patients who were at high risk of liver complications. In fact, in these patients, the LS values suddenly increased from 3 to 6 days before the clinical or laboratory onset of the disease. Since VOD represents a potential life-threatening condition, the availability of a predictive diagnostic test is essential for carrying out timely treatment.
Although risk factors for VOD occurrence have been established, 17, [19] [20] [21] [22] no predictive factors for VOD development have currently been identified.
Two recent studies have evaluated the correlation between LS assessment before HSCT and the development of liver complications. The first study 23 found elevated basal levels of LS (LS48.0 kPa), aspartate amino-transferase, gamma-glutamyl transferase and alkaline phosphatase levels in patients who later developed liver complications.
The second study 14 found an increase in LS values at 4-8 weeks and at 12-20 weeks after HSCT in patients who developed severe liver complications (for example, GvHD, VOD and liver toxicity); however, they did not find any differences in LS between the different complications, they did not describe the pattern of the LS increase and no information regarding the relationship between VOD and LS measurements was assessed.
In our experience, a sudden LS increase during follow-up precedes a diagnosis of VOD. A possible explanation of this behavior is related to the VOD pathogenesis, which is characterized in the first phase by inflammation, sinusoid narrowing, embolized endothelial cells and increased clot formation leading to obstruction of the sinusoids, and subsequently to subendothelial fibrosis of sinusoids and venules. 5 All these events result in hepatic blood congestion, which leads to an increase in LS, as has been documented in patients with congestive heart failure. 24 For this reason, an increase in LS occurs earlier than the clinical and biochemical signs.
The availability of a predictive diagnostic tool for VOD diagnosis is important because a delay in treatment administration of only 2 days 25 results in a worse clinical outcome, which has already been documented. 26 In conclusion, although preliminary, these results show a sudden increase in LS before the appearance of VOD. Consequently, according to the importance of an early diagnosis regarding patient clinical outcome, early specific treatment in patients who had undergone HSCT and are at high risk of VOD, having a documented sudden increase in LS values before overt VOD development is suggested. Additional data on a larger population are obviously needed to confirm the role of LS as a predictor of VOD.
